Science & Technology

Diamyd Medical's furthest developed projects are focused on the treatment of autoimmune diabetes and chronic pain. The company develops therapeutics from two independent platform technologies. One of these platforms relies on the GAD molecule and the other on a viral delivery system to deliver proteins to nervous tissue.

GAD
Glutamic Acid Decarboxylase (GAD) is being developed into a therapeutic vaccine for autoimmune diabetes, the Diamyd® portfolio. Diamyd® is developed in two separate formulations, one for Type 1 diabetes and one for Latent Autoimmune Diabetes in Adults (LADA), and are the company's furthest advanced candidate products. The endogenous human protein GAD may also have therapeutic effects in several neurological disorders including neuropathic pain, Parkinson's disease, migraine headaches, epilepsy, schizophrenia, bipolar disorders and anxiety. Neurologix Inc. has licensed GAD from Diamyd Medical on a non-exclusive basis for the development of new therapies for Parkinson's disease.

NTDDS
The Nerve Targeting Drug Delivery System (NTDDS) is used to deliver genes or therapeutic proteins to the nervous system. Products in the NTDDS portfolio utilize enkephalin or GAD to target chronic pain caused by diabetes, cancer and other diseases. Other NTDDS projects in pipeline involve neuroprotection and treatment of cancer.